Download FOR IMMEDIATE RELEASE Contacts

FOR IMMEDIATE RELEASE
Contacts:
John W. Kozarich
ActivX Biosciences, Inc.
858.558.5558
[email protected]
James Forte or Kim Palmatier
Townsend Inc. for ActivX
858.457.4888
[email protected]
[email protected]
ActivX Biosciences Announces Agreement with Gilead Sciences
for Protein Activity Profiling
LA JOLLA, California, April 6, 2004 – ActivX Biosciences, Inc., a privately held
biotechnology company applying novel chemical technologies and high-throughput
protein analysis to drug discovery and development, announced today it has entered into
an agreement with Gilead Sciences of Foster City, California, USA to further characterize
the activity of certain research compounds supplied by Gilead.
Under the agreement, ActivX will utilize its proprietary technology to analyze specific
proteins to provide a greater understanding of the biological activity of Gilead’s
compounds. Financial terms of the agreement were not announced.
“ActivX’s proprietary technology to rapidly and definitively characterize the activities of
important protein families continues to generate excitement in the pharmaceutical
industry. Our new agreement with Gilead provides ActivX with a unique opportunity to
demonstrate the value of our technology to a leading biopharmaceutical company,” said
John W. Kozarich, PhD., President and Chief Research & Development Officer of
ActivX.
With this partnership, ActivX continues to validate its technology by further building a
strong portfolio of corporate partnerships, which currently include Kyorin Pharmaceutical
Co. and Pfizer.
ActivX Biosciences, Inc., based in La Jolla, California, is a privately held drug discovery
and development company. ActivX’s proprietary chemical technologies and highthroughput protein analysis capabilities are being applied to advancing both its own
internal drug pipeline as well as the development efforts of its pharmaceutical and
biotechnology partners.
By focusing specifically on functional proteins, ActivX addresses disease mechanisms
directly; taking an approach that differs from that of traditional drug discovery and
development methods.
ActivX technology address critical challenges in drug discovery, such as selectivity
profiling of drug candidates across entire protein families in biological samples to guide
their medicinal chemistry optimization; identification of novel drug targets and
biomarkers; and characterization of off-target activities of candidate and established
drugs to understand the basis for their efficacy and toxicity.
For more information on ActivX Biosciences, please visit the company’s Website at
http://www.activx.com
###